NCT01970358 2025-12-29
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
6 trialsNCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01810016 2022-10-12
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT02129075 2021-11-16
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01437605 2019-12-20
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01079741 2018-02-13
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed